Issue of Equity
Updated : 09:01
3 June 2019
Issue of Equity
Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 46,075 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These New Ordinary Shares have been issued to satisfy share options vesting under the 2016 Clinigen Group Sharesave Plan and corresponding 2017 US Purchase Plan and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 5 June 2019.
At admission the issued share capital of the Group will consist of 132,479,167 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 132,479,167. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Group Chief Executive Officer | |
Nick Keher, Group Chief Financial Officer | |
Matt Parrish, Head of Investor Relations | |
Numis Securities Limited - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
James Black / Freddie Barnfield / Freddie Naylor-Leyland | |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw / Deborah Bell | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific. In October 2018, the Group acquired CSM, a specialist provider of packaging, labelling, warehousing and distribution services, with sites in the US and Europe, and iQone, a specialist pharmaceutical company in Switzerland.
For more information, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.